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Abstract
Introduction: The chemokine receptor CCR5 is the main co-receptor for R5-tropic HIV-1 variants. We have previously
described a novel 24-base pair deletion in the coding region of CCR5 among individuals from Rwanda. Here, we investigated
the prevalence of hCCR5D24 in different cohorts and its impact on CCR5 expression and HIV-1 infection in vitro.
Methods: We screened hCCR5D24 in a total of 3232 individuals which were either HIV-1 uninfected, high-risk HIV-1
seronegative and seropositive partners from serodiscordant couples, Long-Term Survivors, or HIV-1 infected volunteers from
Africa (Rwanda, Kenya, Guinea-Conakry) and Luxembourg, using a real-time PCR assay. The role of the 24-base pair deletion
on CCR5 expression and HIV infection was assessed in cell lines and PBMC using mRNA quantification, confocal analysis, flow
and imaging cytometry.
Results and Discussion: Among the 1661 patients from Rwanda, 12 individuals were heterozygous for hCCR5D24 but none
were homozygous. Although heterozygosity for this allele may not confer complete resistance to HIV-1 infection, the preva-
lence of the mutation was 2.41% (95%CI: 0.43; 8.37) in 83 Long-Term Survivors (LTS) and 0.99% (95%CI: 0.45; 2.14) in 613
HIV-1 exposed seronegative members as compared with 0.35% (95% Cl: 0.06; 1.25) in 579 HIV-1 seropositive members. The
prevalence of hCCR5D24 was 0.55% (95%CI: 0.15; 1.69) in 547 infants from Kenya but the mutation was not detected in
224 infants from Guinea-Conakry nor in 800 Caucasian individuals from Luxembourg. Expression of hCCR5D24 in cell lines
and PBMC showed that the hCCR5D24 protein is stably expressed but is not transported to the plasma membrane due to a
conformational change. Instead, the mutant receptor was retained intracellularly, colocalized with an endoplasmic reticulum
marker and did not mediate HIV-1 infection. Co-transfection of hCCR5D24 and wtCCR5 did not indicate a transdominant neg-
ative effect of CCR5D24 on wtCCR5.
Conclusions: Our findings indicate that hCCR5D24 is not expressed at the cell surface. This could explain the higher preva-
lence of the heterozygous hCCR5D24 in LTS and HIV-1 exposed seronegative members from serodiscordant couples. Our
data suggest an East-African localization of this deletion, which needs to be confirmed in larger cohorts from African and non-
African countries.
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1 | INTRODUCTION
Infection with the Human Immunodeficiency Virus-1 (HIV-1)
requires the sequential binding of the envelope glycoprotein
gp120 to the primary receptor CD4 and a chemokine co-
receptor like CCR5 or CXCR4 which induces conformational
changes promoting membrane fusion [1,2]. CCR5 is the main
co-receptor for the R5-tropic HIV-1 variants that are most
commonly transmitted and predominate during early stages of
infection in contrast to the X4 tropic viruses that generally
appear in the advanced stage of infection [3-5]. A variant of
CCR5 containing a deletional mutation of 32-base pairs
impairs cell surface expression of the co-receptor due to an
early termination of translation (Figure 1). Homozygous
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individuals for the CCR5D32 alleles are highly protected from
HIV infection [6-8]. Although heterozygous individuals are sus-
ceptible to HIV-1 infection, their rate of disease progression
is usually slower and long-term survival enhanced, in accor-
dance with a decreased CCR5 expression at the target cell
surface [8-13]. The mutant CCR5D32 was proposed to
heterodimerize with wild-type CCR5 and hence causes its
intracellular retention through a transdominant negative effect
[14-16]. Diminished levels of wtCCR5 in CCR5D32 heterozy-
gotes were also proposed to result from a simple effect of
gene dosage [17].
Accordingly, the CCR5 inhibitor Maraviroc is used in clinical
practice against HIV-1 entry [18], whereas the blocking mono-
clonal antibody PRO 140 against CCR5 is currently in phase
III trial [19]. The critical role of CCR5 in HIV infection was
emphasized by the haematopoietic stem cell transplantation
from CCRD32 homozygous donors to HIV-infected receivers
diagnosed with acute myeloid leukaemia or Hodgkin’s lym-
phoma. This resulted in the complete clearance of the virus,
and the so called “Berlin” and “London” patients are the only
cases of HIV cure to date [20,21]. Several limitations, such as
allogenic stem cell transplantation side-effects or rapid
rebound of pre-existing X4 tropic virus hampered its success-
ful repeat [22-25]. Nevertheless, this discovery stimulated
intense research for CCR5 targeted therapies and strategies
to downregulate CCR5 expression in order to inhibit HIV
infection [26,27].
In addition to CCR5D32, several other CCR5 variants have
been described [28-30]. Some of them were characterized by
major alterations in their functional response to chemokines
or in their potential to modulate HIV-1 disease progression
[6,31-34]. In Kigali, Rwanda, we identified four individuals
heterozygous for a novel 24-base pair deletion in the coding
region of CCR5: an HIV-infected mother and her child and
two individuals from a serodiscordant couple [35]. The 24-
base pair deletion involves nucleotides 61,730 to 61,753,
encoding 8 amino acids located at the top of the second
extracellular transmembrane helix (TM2) (V83–A90) [35] (Fig-
ure 1), and partially overlaps the TXP motif of the chemokine
receptor which is implicated in chemokine-induced receptor
activation, cell surface expression and HIV envelope-depen-
dent fusion [36-39].
The aim of the present study was to investigate the preva-
lence of hCCR5D24 in different cohorts from Rwanda, Kenya,
Guinea-Conakry and Luxembourg to determine whether the
deletion can confer resistance to HIV-1 infection as well as to
decipher its geographical localization. The impact of the
deletion on CCR5 expression and HIV-1 infection was further
assessed in vitro.
2 | METHODS
2.1 | Study population
Approval of the national ethical committees was obtained and
all participants signed an informed consent to participate in
this study in Rwanda, Kenya and Luxembourg. From Rwanda,
buccal cells were collected on swabs between January 2008
and May 2009 from three different cohorts: 386 uninfected
individuals (general population, healthy donors at least
18 years old recruited at the National Reference Hospital of
Kigali), 83 Long-term Survivors (LTS) from a prospective
cohort study on the natural history of HIV infection among
adult women. These women had been identified as HIV posi-
tive in 1986-1989, when antiretroviral treatment was not
available. At the time of enrolment, all women were in clinical
stages I/II for more than 10 years [40], 579 HIV positive and
613 HIV-negative members from a cohort of serodiscordant
couples [41]. Eligibility criteria of the former cohort included
having HIV discordant results (man HIV positive/woman HIV
negative or man HIV negative/woman HIV positive), cohabit-
ing and living in Kigali for at least 12 months, age at recruit-
ment between 21 and 65 years for men, and 21 to 45 years
for women. Both discordant couples and LTS were monitored
in their respective cohorts every three months, and the
recruitment of participants into this study in one single visit
coincided with one follow-up visit in the discordant/LTS stud-
ies. From Kenya, 547 anonymized whole blood samples of
new-borns collected between 1998 and 2000 in Mombasa
from a mother-to-child HIV-1 transmission cohort were
included [42]. The HIV-positive mothers were recruited in
Coast Provincial General Hospital, in the non-intervention arm
of a study evaluating the effect of vaginal lavage with diluted
chlorhexidine on MTCT. All women in active labour, at least
18 years old and living within a reasonable distance to allow
follow-up were eligible. Women admitted in second stage, with
obstetric complications, undergoing caesarean section or deliv-
ering a stillborn were excluded. From Guinea-Conakry, anon-
ymized Dried Blood Spots (DBS) from infants born from any
HIV-infected mother attending the clinic of Medecins Sans
Frontieres (MSF) in Conakry were shipped to Luxembourg for
HIV diagnostic. From Luxembourg, buffy coats of 800 Cau-
casian adults (500 healthy HIV-1 seronegative individuals or
health care workers and 300 HIV-1 infected adults of the
Figure 1. hCCR5D24 mutant is not expressed at the cell surface in cell lines.
(A) The hCCR5D24 deletion does not affect the relative mRNA expression levels of the CCR5 receptor in HEK 293T and HeLa-CD4 cells tran-
siently transfected with pCMV5/HA-wtCCR5 and pCMV5/HA-hCCR5D24 and measured by qRT-PCR. GAPDH was used as a reference gene. (B)
Confocal immunofluorescence analysis reveals hCCR5D24 mutant accumulates in the intracellular compartment but not at the cell surface. CCR5
was stained using anti-HA mAb and the nucleus was stained using DAPI. 10 lm scale. (C and D) wtCCR5 and hCCR5D24 surface or surface +in-
tracellular expression measured by flow cytometry using Ab targeting the NH2-terminal region or ECL2. (D) A GFP reporter vector was added to
each transfection in order to analyse CCR5 expression in transfected populations. (E) Intracellular hCCR5D24 is detectable in transfected HEK
293T cells by imaging cytometry using an Ab targeting the NH2-terminal region but not ECL2. CCR5 surface or surface + intracellular expression
were measured using anti-CCR5 2D7 (ECL 2) and anti-CCR5 T21/8 (N-term) mAbs (C, D and E). Statistical significance was considered when
p ≤ 0.05 (****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05; N = 3 independent experiments). Error bars denote mean  SD. (F) Snake dia-
gram depicting CCR5 topology and identifying the positions occupied by missing residues (red) in the delta 24 (upper panel) and delta 32 (lower
level) receptors respectively.
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Luxembourg HIV cohort collected at the Centre Hospitalier
de Luxembourg between 1992 and 2000) [43] were included.
2.2 | Screening of hCCR5D24
DNA was extracted from buccal swabs, buffy coat or whole
blood using the NucliSENS easyMAGTM system (bioMerieux
SA, Marcy l’Etoile, France) according to the manufacturer’s
recommendations. DNA was extracted from DBS using Chelex
resin [44]. Screening for the hCCR5D24 deletion was per-
formed by allelic discrimination using a custom TaqMan assay
on the ABI 7500 Fast Real Time System (Applied Biosystems,
Brussels, Belgium). The TaqMan genotyping assay contained a
sense (50-GCC-ATC-TCT-GAC-CTG-TTT-TTC-C-30) and anti-
sense (50-GCC-TAT-AAA-ATA-GAG-CCC-TGT-CAA-GA-30) pri-
mer, one VIC-labelled probe for the wild-type (50-CTT-CTG-
GGC-TCA-CTA-TG-MGB-NFQ-30) allele and a FAM-labelled
probe matched to the mutant (50-TCT-TAC-TGC-CGC-CCA-
GTG-MGB-NFQ-30). The probes contained a non-fluorescent
quencher and a minor groove binder (MGB). TaqMan Univer-
sal PCR Master Mix was used (Applied Biosystems, Belgium).
2.3 | Plasmids and cells
Human CCR5 (GenBank:X91492.1) expressed in the pCMV5
vector (Ted Ross, University of Pittsburgh) contains the
sequence of the influenza HA-derived epitope (NH2-YPYDVP-
DYA-COOH) inserted between CCR5 amino acid residues
two and three by PCR [45]. CCR5 fused to FLAG sequence at
its N terminus (NH2-MDYKDDDDK) was constructed by PCR
using the following primers (sense: P-50-AAA-CTT-AAG-CTT-
AAG-AGG-TCA-TTG-TTC-ACC-ATG-GAT-TAC-AAG-GAT-GAC-
GAC-GAT-AAG-GAT-TAT-CAA-GTG-TCA-AGT-CCA-ATC-TAT-
GAC-A-30, antisense 50- ACG-GGC-CCT-CTA-GAG-TCG-AGC-
CCA-CTT-GAG-TCC-GTG-TCA-CAA-GCC-CAC-AGA-TAT-TTC-
CT-30). The 24-bp and 32-bp deletions were inserted into the
CCR5 coding region by inverse PCR using the PfuTurboDNA
Polymerase (Stratagene, Amsterdam, The Netherlands) and
the following primers (sense: P-50-CCG-CCC-AGT-GGG-ACT-
TTG-GAA-ATA-30 , antisense 50-CAG-TAA-GAA-GGA-AAA-AC




(ATCC) and HeLa-CD4 cells (AIDS Research and Reference
Reagent Program, NIAID) were cultured in DMEM containing
10% heat inactivated fetal bovine serum (FBS), 2 mmol/L L-
glutamine, 100 units/mL penicillin, 100 lg/mL streptomycin
and for HeLa-CD4 cells 200 lg/mL geneticin (Invitrogen,
Merelbeke, Belgium). HEK293T and HeLa-CD4 cells were
transfected with DNA (2.5 lg for 1.2 9 106 cells) using Jet-
PRIME (Polyplus). For cotransfections, equimolar amounts of
wtCCR5 and hCCR524, hCCR5D32 or empty pcDNA3.1
(mock) were used for a total amount of 2 lg of DNA. A total
of 0.5 lg of a pCDNA3.1 GFP expression plasmid was added.
Peripheral Blood mononuclear cells (PBMC) were isolated
from healthy donors using Ficoll gradient centrifugation and
maintained in RPMI complemented with 10% FBS, 2 mmol/L
glutamine, 100 units/mL penicillin and 0.1 mg/mL strepto-
mycin. Unstimulated fresh PBMC were transfected with
CCR5 or hCCR5D24 plasmids using the NucleofectorTM
technology from Amaxa Biosytems and the Amaxa Human T
cells Nucleofector kit according to the manufacturer’s proto-
cols.
2.4 | Gene expression analysis
Total mRNA from transfected HEK293T cells was extracted
using the RNeasy Mini Kit (QIAGEN, Venlo, The Netherlands).
RNA concentration was quantified with a Nanodrop Spec-
trophotometer. The High Capacity cDNA RT kit (Applied
Bisosystems) was used for RT-PCR with CCR5D24 Primers
(CCR5D24 sense :50-AAG-GTC-TTC-ATT-ACA-CCT-GCA-GC-
30; CCR5D24 antisense :50-AGC-AGC-GGC-AGG-ACC-A-30)
and a TAMRA Probe (hCCR5D32WT: 50-FAM-ACA-GTC-AG
T-ATC-AAT-TCT-GGA-AGA-ATT-TCC-AG-TAMRA-30). wtCCR5
and hCCR5D24 relative quantification values were measured
in triplicate and calculated according to the 2DDCt method
using the GADPH housekeeping gene for normalization and
values from one healthy control donor.
2.5 | Flow cytometry and imagestream analyses
For co-transfections with wtCCR5 and hCCR5D24 or
hCCR5D32 mutants, a mouse anti-HA tag monoclonal mAb
(HA.C5; Abcam, Cambridge, UK) was revealed with a sec-
ondary goat anti-mouse PE-conjugated Ab for the detection of
hCCR5D24 and hCCR5D32 N-terminal HA-tagged constructs.
The N-terminal Flag-tagged wtCCR5 construct was detected
using a goat anti-ECS (DDDDK) primary Ab (Bethyl Laborato-
ries, Antwerp, Belgium) in combination with a donkey anti-goat
Alexa Fluor 647-conjugated Ab. PE-conjugated anti-
CCR5 mAb T21/8 clone (eBioscience, Vienna, Austria) was
used to stain the N-terminal region of the receptor, whereas
APC-conjugated anti-CCR5 mAb 2D7 clone (Becton Dickinson,
Franklin Lakes, NJ, USA) recognizes the second extracellular
loop (ECL2) of CCR5. For conventional flow cytometry experi-
ments, cells were first stained with LIVE/DEAD Fixable Near-
IR Dead cell stain kit (Thermo Fisher Scientific, Merelbeke,
Belgium) and then fixed for 20 minutes with 1%
paraformaldehyde. Staining of cells in FACS buffer or in 1X
Permeabilization buffer (eBioscience) was performed to
achieve either surface staining or surface + intracellular stain-
ing respectively. For PBMC staining conjugated PE or APC
mouse anti-human CD4 RPA-T4 clone (Becton Dickinson,
USA) was added to gate on CD4+ T cells. For ImageStream
cytometry, cells were stained using BD Cytofix/CytopermTM
(Becton Dickinson, USA) according to the manufacturer’s
instructions and by adding DAPI for nucleus visualization.
Acquisition was performed using the BD LSR Fortessa SORP
Cytometer (Becton Dickinson, USA) and for ImageStream, sin-
gle cells were selected by Gradient RMS_M01, Area_M01 ver-
sus Aspect Ratio_M01 and intensity_M12 (ImageStreamX,
Amnis Corporation, Seattle, WA, USA).
2.6 | Confocal microscopy analysis
Cells were fixed with 4% paraformaldehyde (Sigma-Aldrich,
Overijse, Belgium) during 20 minutes at 4°C. A double stain-
ing was performed with rabbit anti-HA Tag antibody (Sigma,
Belgium), anti-CCR5 purified mouse (Becton Dickinson, USA),
anti-Golgi mouse monoclonal to 58k and an anti-endoplasmic
Arendt V et al. Journal of the International AIDS Society 2019, 22:e25384
http://onlinelibrary.wiley.com/doi/10.1002/jia2.25384/full | https://doi.org/10.1002/jia2.25384
4
reticulum mouse monoclonal to PDI (Abcam). For intracellular
staining 0.1% of Triton 100X (Sigma) was added to the block-
ing buffer. Staining was revealed either with an Alexa Fluor
488- conjugated goat anti-rabbit IgG or an Alexa Fluor 568-
conjugated goat anti-mouse IgG (both from Invitrogen, Bel-
gium), and DAPI for DNA staining. Confocal fluorescent
images were captured using a Zeiss LSM510 META confocal
laser scanning microscope (Jena, Germany) equipped with a
40x Plan-NeoFluar oil immersion objective (numerical aper-
ture 1.3). Confocal images were deconvolved using the Huy-
gens Essential image processing software package (Scientific
Volume Imaging, Netherlands). Pearson’s colocalization corre-
lation coefficients measuring the overlap of green and red
pixel intensities were calculated for regions of interest (ROI)
corresponding to anti-HA-positive cells using the Colocaliza-
tion Threshold plugin for Image J.
2.7 | HIV infection in HeLa cells
Pseudotyped viral particles bearing the HXB2 (X4), ADA (R5)
or BaL (R5) HIV Envs were produced as previously described
[46]. HeLa-CD4 cells were transfected with wtCCR5,
hCCR5D24 or hCCR5D32 as described above and seeded in
96-well plates at a density of 40.104 cells/well after 24 hours.
Forty-eight hours post-transfection, transfected cells (triplicate
wells) were infected with 250 ng/mL of pseudotyped virions
by spinoculation for 2 hours at 1200 g at 25°C, and then
incubated at 37°C for 60 hours. Infection was monitored by
measuring Firefly Luciferase in cell lysates.
2.8 | Statistical analyses
Statistical analyses for the hCCR5D24 prevalence in the dif-
ferent cohorts were performed using a Fisher-T test. The
unpaired Mann-Whitney t-test was used to assess statistical
differences between two independent groups for flow cytome-
try and HIV infection analyses. One-way analysis of variance
(ANOVA) was used to assess statistical differences between
multiple groups. Results were considered significant if
p < 0.05. Results are presented as mean SD. Prism software
(GraphPad, San Diego, CA) was used to perform statistical
analysis. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001.
3 | RESULTS AND DISCUSSION
We first investigated the prevalence of the hCCR5D24 dele-
tion in cohorts of healthy uninfected volunteers, HIV-infected
LTS and HIV-1 seropositive and HIV-1 exposed seronegative
(ESN) members from serodiscordant couples (Table 1). In
Rwanda, among 1661 individuals, 1649 individuals harboured
two wild-type CCR5 alleles (99.27%, 95% CI: 98.74; 99.58)
and 12 individuals were heterozygous for hCCR5D24, repre-
senting a prevalence of 0.73%, (95% CI: 0.42; 1.26) for the
deficient allele. Two of 83 LTS were heterozygous for the
hCCR5D24 allele (2.41%, 95% CI: 0.43; 8.37) compared with
six of 613 ESN (0.99%, 95% CI: 0.45; 2.14), two of 579 HIV-1
seropositive members (0.35%, 95% Cl: 0.06; 1.25), and two of
386 individuals from the general population (0.52%, 95% CI:
0.09; 1.87). The highest prevalence of the hCCR5D24 was
found among LTS and ESN although these differences did not
reach statistical significance compared to HIV-1 seropositive
members (p = 0.078 for LTS and p = 0.288 for ESN), probably
because of the limited number of individuals with a deficient
allele. None of the individuals were homozygous for
hCCR5D24. Ultimately, the predominance of hCCR5D24
heterozygosity in LTS and ESN indicates that this mutation
may mimic hCCR5D32 heterozygosity which reduces the rate
of disease progression [8-12,47,48] and confers some protec-
tion against HIV transmission [49,50].
We next screened for the hCCR5D24 deletion in other
African populations and detected it in 3 of 547 infants from
Mombasa, Kenya [42,51] resulting in a prevalence of 0.55%
(95% CI: 0.15; 1.69). The deletion was not detected in any of
the 224 infants born from seropositive mothers from a MSF
programme of Guinea Conakry nor in 500 HIV-1 seronegative
and 300 HIV-1 seropositive Caucasians from Luxembourg,
thus suggesting a specific East African localization.
This frequency distribution contrasts with the frequency
distribution of CCR5D32, which is high in Caucasians but very
low among Africans and Asians [7,8,52-54]. On the one hand
it has been hypothesized that the distribution of the
CCR5D32 allele in Europe results from the positive selective
pressure attributed by black plague or smallpox [55-58]. On
the other hand, hCCR5D32 was shown to be enriched in
patients with tick-borne encephalitis [59,60] and to be linked
with increased risk of fatal outcome of West Nile Virus infec-
tion [61]. Similarly, we might assume that hCCR5D24 may
have been selected in Africa by other infectious diseases. The
homozygous wtCCR5 individuals are indeed more common in
Crimean-Congo haemorrhagic fever infected patients [62] and
CCR5 knock-out mice are resistant to lethal Dengue virus
infection [63]. In this regard, the putative East African localiza-
tion of the hCCR5D24 is remarkable. Further investigations
are needed to clarify whether its peculiar prevalence in East
African cohorts but absence in Guinea Conakry (West Africa)
and Luxembourg may be related to a negative or positive
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613 6 0.98 (0.36 to 2.13)a
Long-Term Survivors 83 2 2.41 (0.29-8.70)b
ap = 0.288 HIV-negative versus HIV-positive members from serodis-
cordant couples; bp = 0.078 LTS versus HIV-positive members from
serodiscordant couples.
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selective pressure due to increased or decreased susceptibility
to infections. Ultimately, Africa is characterized by an exten-
sive ethnic diversity with ancestral population genetic clusters
that correlate with self-described ethnicity, shared cultural
and/or linguistic properties [64]. This could also explain the
geographical localization of the hCCR5D24 in East Africa.
Our cohort analysis suggests that hCCR5D24 heterozygos-
ity may delay progression to AIDS but the limited size of the
cohorts, the low prevalence of the hCCR5D24 allele and the
absence of homozygous individuals did not provide enough
statistical evidence. We therefore used an in vitro approach to
assess the impact of the CCR5 variant.
Homozygous individuals harbouring hCCR5D32 are highly
resistant to HIV-1 infection [6-8] due to a premature trunca-
tion of the receptor which abolishes its expression at the cell
surface [7,65] similarly to other natural CCR5 mutants [31].
To investigate whether hCCR5D24 mutant cell-surface
expression was similarly impaired, we transiently transfected
HEK-293T and HeLa-CD4 cells with a pCMV5 expression
plasmid containing wild-type hCCR5 or mutant hCCR5D24
sequences, both including an HA tag in the N-terminus of the
receptor. Expression levels of wtCCR5 and hCCR5D24 mRNA
were found to be equivalent in each cell line 24 hours post-
transfection (Figure 1A). We next investigated the receptor
cell surface and intracellular expression by confocal micro-
scopy. HA tag staining revealed that the hCCR5D24 receptor
was not expressed at the cell surface but rather accumulated
in the cytoplasm of HEK 293T and HeLa-CD4 cells (Fig-
ure 1B). The intense perinuclear staining suggested that the
mutant receptor is efficiently synthesized but retained intra-
cellularly. Impaired cell-surface expression of the mutant
receptor was further confirmed by flow cytometry (Figure 1C,
D and Figure S1A). HEK-293T and HeLa-CD4 cells were then
cotransfected with either hCCR5D24 or wtCCR5 and a GFP
reporter vector. Flow cytometry was performed using T21/8
mAb and the conformation-sensitive 2D7 mAb [66] which rec-
ognize the N-terminal region and the second extracellular loop
(ECL2) of CCR5 respectively. CCR5 staining was performed
at the cell surface alone by fixing and staining cells or at the
surface and intracellularly by fixing, permeabilizing and stain-
ing cells. CCR5 expression was analysed in GFP-positive cells
to select for the transfected population. We observed that
GFP-negative cells did not express any wt nor mutant CCR5
(data not shown). As shown in Figure 1C,D, hCCR5D24 was
not detected by any of the mAbs at the cell surface, while the
T21/8 mAb targeting the N-terminal region of hCCR5
revealed similar levels of wtCCR5 and hCCR5D24 when the
cells were permeabilized. hCCR5D24 was not detectable with
clone 2D7, which targets ECL2 (Figure 1C,D). These results
suggest that the hCCR5D24 deletion, located at the top of
TM2 close to the disulphide bridge linking ECL1 to ECL2,
induced a conformational change in ECL2 [67,68]. This confor-
mational change could lead to protein misfolding and may
interfere with its surface export, resulting in its intracellular
accumulation [69]. These observations were confirmed by
imaging cytometry (Figure 1E and Figure S1B). hCCR5D24 or
wtCCR5 expressing HEK293T cells were stained either with
T21/8 for surface expression and 2D7 for intracellular and
surface expression or T21/8 for intracellular and surface
expression and 2D7 for surface expression. Micrographs of
three representative cells in each condition clearly indicate
that hCCR5D24 is only detectable intracellularly using the
T21/8 antibody. Similar results were obtained in CD4+ T cells
from unstimulated human PBMC with the N-term targeting
clone (T21/8) and the conformation-sensitive 2D7 mAb as
well as with a primary anti-HA tag antibody (Figure 2A) show-
ing the significant absence of surface expression of the mutant
protein (Figure 2B).
We next investigated whether hCCR5D24 has a transdomi-
nant negative effect on wtCCR5 surface expression. To distin-
guish between wtCCR5 and the mutated hCCR5D24, we
inserted a FLAG sequence at the NH2-terminal end of
wtCCR5. FLAG-wtCCR5 was cotransfected in HEK 293T and
HeLa-CD4 cells with HA-hCCRD24, HA-hCCR5D32 as a con-
trol or the empty pcDNA vector in equimolar ratios to mimic
co-expression of wtCCR5 and the mutants. A GFP reporter
vector was added to analyse CCR5 expression in transfected
populations. CCR5 surface or surface + intracellular expres-
sion was analysed by flow cytometry using anti-FLAG and
anti-HA mAb (Figure 3A,B and Figure S2). wtCCR5 was
detected in each condition using the anti-FLAG mAb, as
expected. Again we observed hCCR5D24 and hCCR5D32
expression using the anti-HA mAb only when cells were per-
meabilized prior to staining, but not when only surface expres-
sion was evaluated. When FLAG-wtCCR5 and HA-hCCRD24
were cotransfected, both forms were detectable intracellularly.
Importantly their co-expression did not affect the levels of
surface or surface + intracellular wtCCR5 expression, indicat-
ing that hCCRD24 has no transdominant negative effect on
wtCCR5 expression when expressed in an equivalent molar
ratio. Similar results were recorded when wtCCR5 was
cotransfected with HA-hCCR5D32 (Figure 3A,B).
To examine the impact of hCCRD24 on HIV-1 infection,
HeLa-CD4 cells were transfected with FLAG-wtCCR5 or HA-
hCCRD24 alone, or cotransfected with both FLAG-wtCCR5-
FLAG + HA-hCCRD24 at a 1:1 ratio. Forty-eight hours post-
transfection, transfected cells were infected with CCR5
(ADA8 and BaL) or CXCR4 (HXB2) tropic HIV-1 pseu-
doviruses. HeLa-CD4 cells, which naturally express CXCR4
but not CCR5, were infected with HXB2 but not with CCR5
tropic pseudoviruses, as expected. HeLa-CD4 cells expressing
wtCCR5 demonstrated a dramatically enhanced susceptibility
to CCR5 tropic infection (Figure 3C). In contrast, hCCRD24
expression did not render HeLa-CD4 cells susceptible to
ADA8 or BaL infection. Interestingly HeLa-CD4 cells cotrans-
fected with wtCCR5 + hCCRD24 mediated entry of ADA8
and BaL pseudovirions to levels comparable to HeLa-CD4-
wtCCR5 cells, thereby confirming the absence of any trans-
dominant negative effect of hCCR5D24 or hCCR5D32 on
wtCCR5.
Our results are in line with previous studies reporting
impaired or reduced cell-surface expression and cytoplasmic
retention of several CCR5 mutant proteins such as human
CCR5D32 [7,65], human CCR5 C101X, FS299 and CCR5-893
() mutants [31,32] or the A73V mutant, which is located in
the second transmembrane domain, close to the 24-base pair
deletion [31]. A similar effect was reported for sooty and red-
capped mangabeys CCR5D24 [70-72] although the 24-base
pair deletion found in CCR5 from African simian species is
not located in the same region as human CCR5D24.
Levels of CCR5 expression were previously described to be
a key determinant in HIV entry [73-75] and hence
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pathogenesis [76]. Accordingly, we report that the absence of
surface expression of hCCR5D24 provides a complete protec-
tion against HIV-1 infection, as previously observed for
hCCR5D32 homozygous individuals [6-8]. In heterozygous
wtCCR5/CCR5D32 individuals, resistance to HIV transmission
and reduced disease progression rate to AIDS were linked to
a decrease in CCR5 expression at the target cell surface [8-
12,49,50]. A transdominant effect of the mutant protein was
proposed, resulting in the intracellular sequestration of





































Figure 2. hCCR5D24 is not expressed at the cell surface of CD4+ T cells in PBMCs.
(A and B). CCR5 surface and intracellular expression was measured by flow cytometry in human CD4+ T cells from PBMCs transiently transfected
with pCMV5/HA-wtCCR5 and pCMV5/HA-hCCR5D24 using anti-CCR5 2D7 (ECL 2) and anti-CCR5 T21/8 (N-term) mAbs (A) and anti-HA mAbs
(C). Statistical analyses of the flow cytometry experiments from (A). Statistical significance was considered when p ≤ 0.05 (**p ≤ 0.01, *p ≤ 0.05;
N = 3 independent experiments). Error bars denote mean  SD.
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Figure 3. hCCR5D24 mutant has no transdominant negative effect on wtCCR5.
(A) HEK-293T and HeLa-CD4 cells were transfected with FLAG-wtCCR5, HA-hCCRD24 and HA-hCCR5D32 alone or cotransfected with FLAG-
wtCCR5 and HA-hCCRD24 or HA-hCCR5D32 in equimolar ratio. (A) GFP reporter vector was added to each transfection in order to analyse
CCR5 expression in transfected populations. CCR5 surface or surface + intracellular expression was analysed by flow cytometry using anti-FLAG
and anti-HA mAbs. (B) Quantification of the flow cytometry experiment from A. (C) HeLa-CD4 cells were transfected with FLAG-wtCCR5, HA-
hCCRD24 alone or cotransfected with FLAG-wtCCR5 and HA-hCCRD24 in equimolar ratios. Transfected cells were infected with HXB2, ADA8 or
BaL pseudovirus expressing a Luciferase reporter gene. HIV-1 infection was quantified by measuring Luciferase-dependent luminescence. Statisti-
cal significance was considered when p ≤ 0.05 (****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01, *p ≤ 0.05; N = 3 independent experiments). Error bars
denote meanSD.
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or wtCCR5 + hCCR5D32 were cotransfected using an equiva-
lent molar ratio, the export of the wild-type protein and target
cell infectability by CCR5 tropic HIV-1 viruses were unaf-
fected. Our results indicate that hCCR5D24 and hCCR5D32
have no negative transdominant effect in this particular exper-
imental setting aiming at mimicking equivalent gene expres-
sion of hCCR5D24 and wtCCR5. We also tested
cotransfections at a 3:1 molar ratio (for hCCR5D24 and
wtCCR5 respectively) as previously performed by Benkirane
et al. [14] who showed transdominant inhibition of CCR5-
mediated HIV-1 infection by hCCR5D32. Although we
observed a trend towards decreased wtCCR5 expression
when hCCR5D24 was cotransfected in large excess, the MFI
of wtCCR5 staining in the cotransfection were not signifi-
cantly different from the wtCCR5 staining when transfected
alone in HEK293 T cells and HeLa-CD4 cells (Figure S3A,B).
Furthermore, we did not observe any significant impact of
hCCR5D24 overexpression on the susceptibility of HeLa-CD4
cells to infection with CCR5 tropic pseudoviruses (Figure S3C).





























































































































Figure 4. The hCCR5D24 mutation increases CCR5 colocalization with Endoplasmic Reticulum but not Golgi markers.
HEK 293T and HeLa-CD4 cells were transiently transfected with pCMV5/HA-wtCCR5 and pCMV5/HA-hCCR5D24. Representative confocal
micrographs of CCR5, ER (A) and Golgi (C) staining using anti-HA, anti-PDI and anti-58K mAbs respectively. Pearson’s colocalization correlation
coefficients between anti-HA and anti-PDI (B) or anti-58k (D) staining were calculated for regions of interest (ROI) corresponding to anti-HA posi-
tive cells using Colocalization Threshold (Image J). Statistical significance was considered when p ≤ 0.05, **p ≤ 0.01, *p ≤ 0.05; N = 3 indepen-
dent experiments). Error bars denote mean  SD. 10 um scale.
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setting hCCRD24 has no significant transdominant negative
effect on wtCCR5. Since Benkirane et al. have used a readout
that detects viral entry and fusion while our assay detects
viral entry only, it is possible that the negative transdominant
effect reported by Benkirane et al. reflects an impact of
mutant CCR5 receptors on cell-to-cell fusion mainly, which
our assay did not capture. Further experiments would be
needed to confirm this hypothesis. Therefore, we propose a
simple mechanism of gene dosage rather than a negative
transdominant effect in hCCR5D32 and hCCR5D24 heterozy-
gotes as previously suggested [17]. Noteworthily, our experi-
mental setting of co-transfection may not fully reflect the
complex in vivo situation found in heterozygous patients.
The cytoplasmic hCCR5D24 accumulation suggests that
mutant receptor conformational changes could induce a
disruptive intracellular secretory pathway and mutant
retention in the Golgi apparatus or the endoplasmic reticu-
lum (ER). To identify the subcellular sites of mutant recep-
tor retention, we immunostained HEK-293T and HeLa-CD4
cells transiently expressing HA-wtCCR5 or HA-hCCR5D24
using an anti-HA tag Ab with the anti-58k or anti-PDI
mAbs as Golgi and endoplasmic reticulum (ER) markers
respectively (Figure 4A,B). Confocal microscopy revealed
that wtCCR5 was systematically distributed at the plasma
membrane in both cell lines. In contrast, cells expressing
hCCR5D24 demonstrated an intracellular staining co-loca-
lizing with the ER marker but not the Golgi marker. These
results indicate that conformational changes induced by the
hCCR5D24 deletion impair CCR5 trafficking, causing its
retention into the ER and preventing a correct addressing
to the cell surface. Likewise, the CCR5-893 (-) and C-term-
inal mutants lacking six, five, four or three transmembrane
domains or mutated in the basic domain (-KHIAKRF-) and
the cysteine cluster (-CKCC-) were also retained in the ER
[14,17,77,78].
4 | CONCLUSIONS
Our results suggest that the hCCR5D24 deletion affects
ECL1/ECL2 conformation, CCR5 addressing at the cell sur-
face and thus protect from HIV-1 infection although it has no
transdominant negative effect on wtCCR5 expression. These
findings might explain the higher prevalence of the heterozy-
gous deletion in Rwandese LTS individuals and in seronegative
partners from serodiscordant couples. The small size of our
cohorts together with the low prevalence of the mutation may
have limited the proper evaluation of hCCR5D24 function in
HIV infection. We might also speculate that the absence of
homozygous hCCR5D24 deletion carriers reflects a negative
selection due to the high burden of infections in sub-Saharan
Africa. This hypothesis is supported by a recent study showing
a deleterious effect of the homozygous hCCR5D32 using
death register information of 409,693 individuals of British
ancestry [79]. Analysis of larger cohorts is nevertheless
needed to confirm this assumption and the East African local-
ization of the hCCR5D24 deletion.
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Figure S1. hCCR5D24 mutant is not expressed at the cell sur-
face of cell lines. (A) Representative dot plots of wtCCR5 or
hCCR5D24 expressing HEK-293T and HeLa-CD4 cells stained
at the surface or surface + intracellularly with 2D7 and T21/8
mAbs. (B) Quantification of the imaging cytometry experi-
ments from Figure 1D. Statistical significance was considered
when p ≤ 0.05 (****p ≤ 0.0001, ***p ≤ 0.001, **p ≤ 0.01,
*p ≤ 0.05; N = 3 independent experiments). Error bars
denote mean  SD.
Figure S2. hCCR5D24 mutant has no transdominant negative
effect on wtCCR5 using a 1:1 equimolar ratio. (A) Representa-
tive dot plots of wtCCR5 or hCCR5D24 expressing HEK-
293T and HeLa-CD4 cells stained at the surface or surface +
intracellularly with anti-FLAG and anti-HA mAbs.
Figure S3. hCCR5D24 mutant has no transdominant negative
effect on wtCCR5 using a 3:1 ratio. (A) HEK-293T and HeLa-
CD4 cells were transfected with FLAG-wtCCR5, HA-
hCCRD24 and HA-hCCR5D32 alone or cotransfected with
FLAG-wtCCR5 and HA-hCCRD24 or HA-hCCR5D32 at 1:1
or 3:1 ratios. A GFP reporter vector was added to each trans-
fection in order to analyse CCR5 expression in transfected
populations. CCR5 surface or surface + intracellular expres-
sion was analysed by flow cytometry using anti-FLAG and
anti-HA mAbs. (A) Reports quantification of the flow cytome-
try experiments. (B) HeLa-CD4 cells were transfected with
FLAG-wtCCR5, HA-hCCRD24 alone or cotransfected with
FLAG-wtCCR5 and HA-hCCRD24 at a 3:1 ratio as in (A). (C)
Transfected cells were infected with HXB2, ADA8 or BaL
pseudovirus expressing a Luciferase reporter gene 48 hours
post-transfection. HIV-1 infection was quantified by measuring
Luciferase-dependent luminescence. Statistical significance was
considered when p ≤ 0.05 (****p ≤ 0.0001, ***p ≤ 0.001,
**p ≤ 0.01, *p ≤ 0.05; N = 3 independent experiments). Error
bars denote mean  SD.
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